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Insulin-like growth factor-I (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour
development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a
higher risk of cancers at speciﬁc sites, including breast and prostate. No prospective study has examined the association
between circulating IGF-I concentrations and melanoma risk. A nested case–control study of 1,221 melanoma cases and 1,221
controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of
520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios
(ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were
conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status,
alcohol intake, marital status, physical activity and in women only, use of menopausal hormone therapy. There was no
signiﬁcant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest ﬁfth = 0.93 [95%
conﬁdence interval [CI]: 0.71 to 1.22]). There was no signiﬁcant heterogeneity in the association between IGF-I concentrations
and melanoma risk when subdivided by gender, age at blood collection, BMI, height, age at diagnosis, time between blood
collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no
evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma.
Int. J. Cancer: 144, 957–966 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
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What’s new?
A possible association between the insulin-like growth factor (IGF-I) and the risk of melanoma has been proposed, but with
inconclusive results so far. In this prospective study, the authors found no evidence for an association between circulating IGF-
I concentrations and melanoma risk. Although details on major risk factors like sun exposure were missing, the large sample
size with more than 1000 incident melanoma cases underscores the relevance of the ﬁnding.
Introduction
Worldwide there were an estimated 350,000 new cases of mel-
anoma and 60,000 deaths from melanoma in 2015.1 Exposure
to ultraviolet radiation (speciﬁcally, intermittent exposure),
and phenotypic characteristics such as fairer skin colour,
blond or red hair and multiple naevi and freckles are estab-
lished risk factors for melanoma.2–4 There are also other puta-
tive or possible risk factors for melanoma including
occupational exposure to chemicals and ionising radiation.5
Insulin-like growth factor-I (IGF-I) is a polypeptide hor-
mone that stimulates cell division and inhibits apoptosis; it is
through these properties that it is thought to play a role in the
development and progression of carcinogenesis.6 Prospective
studies have shown that higher circulating concentrations of
IGF-I are associated with a higher risk of cancers at speciﬁc
sites, including the breast,7 prostate8 and possibly the thyroid.9
Three case–control studies have examined the relationship
between circulating IGF-I concentrations and risk of mela-
noma, but the results were not consistent. One study found
an inverse relationship between circulating IGF-I concentra-
tion and risk of melanoma,10 but two studies found an posi-
tive association.11,12 The results of case–control studies may
be unreliable if the development of melanoma affects circulat-
ing IGF-I concentrations, or if bias was introduced in the
selection of controls.13 Given this uncertainty, we examined
the association between circulating IGF-I concentrations mea-
sured in adulthood and the subsequent risk of melanoma in a
case–control study nested within the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort.
Methods
Study population
The study design, including the recruitment, blood collection
and follow-up procedures of EPIC has been described previ-
ously.14 Brieﬂy, between 1992 and 2000 approximately
520,000 participants, mostly aged between 35 and 70 years,
were recruited from 23 centres in 10 European countries
(Denmark, France, Germany, Greece, Italy, Netherlands, Nor-
way, Spain, Sweden and the United Kingdom). Participants
provided information on sociodemographic characteristics,
dietary intakes and lifestyle factors. The study was approved
by the International Agency for Research on Cancer Ethics
Committee and local ethics committees in the participating
countries. All participants gave written informed consent.
Selection of cases and controls
In most centres, follow-up for cancer incidence and mortality
was conducted via record linkage with regional and national
registries. In France, Germany and Greece, follow-up was by a
combination of methods, including health insurance records,
cancer and pathology registries and active follow-up through
study subjects and their next-of-kin.15
Cases were participants who were diagnosed with incident
invasive melanoma of the skin (WHO international classiﬁca-
tion of diseases-oncology third edition (ICD-O-3) Codes
8,720–8,790, with ﬁfth digit behaviour Code 3 signifying inva-
sive malignancies) during follow-up, and who had donated a
blood sample and had not been diagnosed with cancer (except
for nonmelanoma skin cancer) at baseline, and had not been
diagnosed with other tumours (except nonmelanoma skin
cancer) before the melanoma diagnosis. Superﬁcial spreading
melanomas were deﬁned as tumours with ICD-O-3 morphol-
ogy code 8743/3, and nodular melanomas as those with ICD-
O-3 morphology code 8721/3. Melanomas of the head and
neck were tumours with international classiﬁcation of diseases
10th edition (ICD-10) site codes C44.0-C44.4, melanomas of
the trunk were those with ICD-10 site code C44.5, melanomas
of the upper limbs were those with ICD-10 site code C44.6,
and melanomas of the lower limbs were those with ICD-10
site code C44.7. Participants were eligible for selection as a
control if they had provided a blood sample at baseline, and
were alive and without a cancer diagnosis (other than nonme-
lanoma skin cancer) at the time of the diagnosis of the index
case. Randomly chosen controls were matched (1:1) to each
case using incidence density sampling.16 The matching criteria
were: study centre, gender, age at blood collection ( 1 year),
and date ( 3 months), time of day ( 3 hr), and fasting sta-
tus (< 3 hr, 3 to 6 hr, > 6 hr) at blood collection. The present
study includes 1,221 cases and 1,221 controls (523 male cases
and controls; 698 female cases and controls).
Laboratory measurements
Approximately 75% of participants provided a blood sample
at recruitment.15 In most centres whole blood was transported
to a local laboratory, processed within 24 hr, and transported
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Table 1. Characteristics of the melanoma cases and controls
Controls Cases pdifference
1
Men
n 523 523
Mean (SD) age at blood collection (years) 55.1 (8.1) 55.1 (8.1) *
Mean (SD) height (cm) 175.3 (6.9) 176.5 (7.0) 0.004
Mean (SD) BMI (kg/m2) 26.2 (3.5) 26.4 (3.3) 0.322
Education
Primary/none 35.7 (183) 29.7 (151) 0.048
Secondary 38.0 (195) 37.8 (192)
Degree 26.3 (135) 32.5 (165)
Alcohol intake (g/day)
< 1 9.2 (48) 8.7 (45) 0.718
1–7 26.8 (140) 24.0 (125)
8–19 27.9 (146) 29.0 (151)
20–39 21.8 (114) 21.4 (111)
 40 14.3 (75) 16.9 (88)
Smoking status
Never 34.2 (177) 37.0 (190) 0.023
Former 37.1 (192) 41.6 (214)
Current 28.8 (149) 21.4 (110)
Physical activity
Inactive 20.3 (103) 15.6 (79) 0.259
Moderately inactive 33.1 (168) 34.7 (176)
Moderately active 22.1 (112) 24.4 (124)
Active 24.6 (125) 25.4 (129)
Mean (95% CI) IGF-I concentrations (nmol/L) 18.2 (17.7–18.6) 18.2 (17.8–18.6) 0.912
Women
n 698 698
Mean (SD) age at blood collection (years) 53.9 (9.0) 53.9 (9.0) *
Mean (SD) height (cm) 162.2 (6.6) 163.0 (6.4) 0.016
Mean (SD) BMI (kg/m2) 25.3 (4.3) 25.3 (4.6) 0.948
Education
Primary/none 32.3 (218) 30.5 (206) 0.604
Secondary 49.9 (337) 49.8 (336)
Degree 17.8 (120) 19.7 (133)
Alcohol intake (g/day)
< 1 28.8 (201) 29.7 (207) 0.972
1–7 35.7 (249) 36.5 (255)
8–19 24.1 (168) 23.2 (162)
20–39 8.9 (62) 8.3 (58)
 40 2.6 (18) 2.3 (16)
Smoking status
Never 53.3 (369) 52.6 (361) 0.890
Former 26.8 (186) 26.5 (182)
Current 19.9 (138) 21.0 (144)
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to be stored centrally in liquid nitrogen at −196C at the
International Agency for Research on Cancer. In Denmark, all
blood samples were stored locally in nitrogen vapour at
−150C, and in Sweden all blood samples were stored in elec-
tric freezers at −70C. In the Oxford cohort, samples were
sent at ambient temperature to a central laboratory in Nor-
folk, UK with a mean transit time of 1.5 days.
IGF-I concentration was measured in serum samples,
except for the participants from Norway and Umeå (Sweden),
for which citrated plasma and EDTA plasma samples were
used, respectively. IGF-I concentration was measured in the
Cancer Epidemiology Unit (Oxford, United Kingdom) using
the automated IDS-iSYS immunoassay system from Immuno-
diagnostic Systems Ltd (Tyne & Wear, United Kingdom).17
Laboratory personnel were blind to the case–control status of
the samples and each case–control set was analysed in the
same batch, together with duplicate quality control samples.
The intra- and inter-assay coefﬁcients of variation were 3.9%
and 4.7% at an overall mean concentration of 14.2 nmol/l.
Statistical analyses
All statistical analyses were run using Stata version 14.1 (Stata
Corp, College Station, TX). Participant characteristics were
compared between cases and controls, for men and women
separately, using the paired-sample t test for continuous vari-
ables and the chi-square test for categorical variables.
IGF-I concentration was logarithmically transformed (using
the natural log transformation) to approximate a normal distri-
bution. Among controls only, geometric mean serum IGF-I con-
centrations by participant characteristics were investigated using
analysis of variance (ANOVA), adjusted for batch, age at blood
collection (as a continuous variable), gender, country and alcohol
intake. Tests for linear trends across categories were performed
by scoring categories with consecutive integers.
Odds ratios (ORs) and 95% conﬁdence intervals (CIs) for
melanoma by quintiles of gender-speciﬁc serum IGF-I con-
centration at baseline (based on the gender-speciﬁc distribu-
tions in the controls) were estimated using conditional logistic
regression, conditioned on the matching variables. In the mul-
tivariable model, to allow for ﬁner adjustment for age, the
model was adjusted for age at blood collection (in months, as
a continuous variable), as well as education (primary/none,
secondary, degree), height (gender-speciﬁc quartiles), BMI
(gender-speciﬁc quartiles), smoking status (never, former, cur-
rent), alcohol intake (<1, 1–7, 8–19, 20–39, >40 g/d), marital
status (married/cohabiting, unmarried/not cohabiting), physi-
cal activity (inactive, moderately inactive, moderately active,
active18), and in women only, use of menopausal hormone
therapy (current, not current). For all covariates, any missing
values were assigned to a separate category. The odds of mela-
noma associated with a doubling of IGF-I concentration were
investigated as described above but using the logarithm to the
base 2 of serum IGF-I concentration.
Table 1. (Continued)
Controls Cases pdifference
1
Physical activity
Inactive 23.9 (158) 23.1 (152) 0.801
Moderately inactive 33.7 (223) 36.4 (240)
Moderately active 22.1 (146) 21.7 (143)
Active 20.3 (134) 18.8 (124)
Parity
Nulliparous 13.5 (88) 12.7 (83) 0.480
1 18.0 (117) 14.8 (97)
2 43.8 (285) 46.1 (302)
3 16.9 (110) 18.9 (124)
4 or more 7.8 (51) 7.5 (49)
Oral contraceptive use
Never 42.6 (289) 42.1 (287) 0.876
Ever 57.4 (390) 57.9 (394)
Menopausal hormone therapy use
Not current 81.9 (546) 80.1 (534) 0.403
Current 18.1 (121) 19.9 (133)
Mean (95% CI) IGF-I concentrations (nmol/L) 17.4 (17.0–17.7) 17.5 (17.1–17.9) 0.593
1 Values are % (n) unless otherwise stated.
2 The paired-sample t test was used for continuous variables and the chi-square test was used for categorical variables. *p values were not calculated
for matching factors.
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Table 2. Adjusted geometric mean IGF-I concentrations (nmol/L) by participant characteristics in 1221 controls
Characteristic n Geometric mean (95% CI) Pdifference
1
Gender2
Men 523 18.2 (17.8–18.6) 0.002
Women 698 17.3 (17.0–17.7)
Age at blood collection (years)3
<50 292 20.0 (19.3–20.6) <0.001
50–54 302 17.9 (17.4–18.5)
55–59 282 16.9 (16.4–17.4)
60–64 207 16.8 (16.2–17.5)
 65 138 15.9 (15.2–16.6)
Country4
Denmark 258 17.3 (16.6–18.1) 0.004
France 49 18.5 (17.1–20.1)
Germany 146 17.0 (15.9–18.1)
Greece 18 16.5 (14.5–18.9)
Italy 110 18.3 (17.3–19.4)
Netherlands 109 19.5 (18.2–20.9)
Norway 27 14.4 (11.8–17.5)
Spain 70 17.5 (16.3–18.7)
Sweden 272 17.6 (16.5–18.8)
UK 162 18.1 (17.2–19.1)
Education
Primary/none 401 17.3 (16.9–17.8) 0.118
Secondary school 532 17.8 (17.4–18.2)
Degree 255 18.1 (17.5–18.8)
Height (quartiles)5
Lowest quartile 336 17.4 (16.9–17.9) 0.131
2 347 17.5 (17.0–18.0)
3 280 18.3 (17.7–18.9)
Highest quartile 258 17.8 (17.2–18.4)
BMI (kg/m2)6
Lowest quartile 302 17.4 (16.8–17.9) 0.036
2 315 18.2 (17.6–18.7)
3 306 18.0 (17.5–18.6)
Highest quartile 298 17.3 (16.7–17.8)
Alcohol intake (g/day)7
<1 249 18.3 (17.6–18.9) 0.023
1–7 389 18.0 (17.5–18.5)
8–19 314 17.6 (17.1–18.2)
20–39 176 17.2 (16.5–17.9)
 40 93 16.4 (15.5–17.4)
Smoking status
Never 546 17.5 (17.1–17.9) 0.440
Former 378 17.9 (17.4–18.4)
Current 287 17.8 (17.2–18.3)
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Using conditional logistic regression, conditioning on the
matching factors and adjusting for the covariates listed above
(where relevant), we also examined the association between IGF-
I and melanoma subdivided by major participant characteristics:
gender, age at blood collection (< 55 years, ≥ 55 years), BMI
(< 25 kg/m2, ≥ 25 kg/m2), height (gender-speciﬁc medians:
< 176 cm (men) or < 163 cm (women), ≥ 176 cm (men)
or ≥ 163 cm (women)), and age at case diagnosis (< 60 years,
≥ 60 years). In addition, to investigate the possibility of reverse
causality we examined the association between IGF-I and mela-
noma subdivided by time between blood collection and diagnosis
(< 4 years, ≥ 4 years). Finally, to explore whether IGF-I may be
differentially associated with subtypes of melanoma, we exam-
ined the association between IGF-I and melanoma risk in catego-
ries of anatomical site (head and neck, trunk, upper limbs, and
lower limbs) and histological subtype (superﬁcial spreading and
nodular melanoma) of the tumour. For these analyses, controls
were assigned to the same category as their matched case. For
the BMI subgroup analysis, participants were only included if
both the case and matched control had a BMI <25 kg/m2, or if
both case and matched control had a BMI ≥ 25 kg/m2, with sim-
ilar rules for the analyses subdivided by height and age at blood
collection. Tests for heterogeneity of risk between subgroups
were performed using the likelihood ratio test, comparing models
with and without the interaction term between the logarithm of
circulating IGF-I concentration and the variable of interest.
All statistical tests were two-sided, and p < 0.05 was con-
sidered statistically signiﬁcant.
Results
Among men, cases were slightly taller, were more likely to
have a university degree, and less likely to be current smokers,
compared to the controls. Among women, cases were also
slightly taller, but were otherwise similar to controls with
regards to the characteristics listed in Table 1. Among the
Table 2. (Continued)
Characteristic n Geometric mean (95% CI) Pdifference
1
Physical activity
Inactive 261 17.8 (17.2–18.4) 0.546
Moderately inactive 399 17.7 (17.2–18.2)
Moderately active 271 17.8 (17.2–18.4)
Active 263 17.3 (16.7–17.9)
Marital status
Married/co-habiting 677 17.8 (17.5–18.2) 0.719
Unmarried/not co-habiting 194 17.7 (17.0–18.4)
Parity
Nulliparous 88 17.9 (16.9–18.9)
One 117 17.5 (16.7–18.4) 0.062
Two 286 16.9 (16.4–17.4)
Three 110 17.7 (16.9–18.6)
Four or more 51 16.0 (14.9–17.2)
Oral contraceptive use
Never 289 17.5 (17.0–18.1) 0.351
Ever 390 17.2 (16.7–17.6)
Menopausal hormone therapy use
Not current 546 17.5 (17.2–17.9) 0.011
Current 121 16.3 (15.6–17.2)
Adjusted for batch, age at blood collection, gender, country and alcohol intake unless otherwise stated.
1p values refer to tests of difference between the logarithm of IGF-I concentration in the separate categories (excluding unknowns) calculated by
ANOVA.
2Adjusted for batch and age at blood collection.
3Adjusted for batch and gender.
4Adjusted for batch, age at blood collection and gender.
5The quartile ranges for height for men were: 150.00–171.00 cm (Quartile 1), 171.20–176.00 cm (Quartile 2), 176.13–181.00 cm (Quartile 3), and
181.30–195.00 cm (Quartile 4) and for women were: 142.00–158.36 cm (Quartile 1), 158.40–163.00 cm (Quartile 2), 163.08–167.00 cm(Quartile 3)
and 167.10–184.00 cm (Quartile 4).
6The quartile ranges for BMI for men were: 16.58–23.97 kg/m2 (Quartile 1), 24.06–26.01 kg/m2 (Quartile 2), 26.02–28.25 kg/m2 (Quartile 3), and
28.29–39.58 kg/m2 (Quartile 4) and for women were: 15.15–22.19 kg/m2 (Quartile 1), 22.22–24.45 kg/m2 (Quartile 2), 24.50–27.60 kg/m2(Quartile
3) and 27.62–43.19 kg/m2 (Quartile 4).
7Adjusted for batch, age at blood collection, gender and country.
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cases, the mean time from blood collection to diagnosis was
6.5 years.
Among the controls, geometric mean IGF-I concentrations
were signiﬁcantly lower in women, in those who were older at
blood collection, and in those who drank the most alcohol
(Table 2). Among women, current menopausal hormone ther-
apy users had lower mean IGF-I concentrations. The lowest
concentrations of IGF-I were in the ﬁrst and fourth quartiles
of BMI and the highest concentrations were in the second and
third quartiles. Circulating IGF-I concentrations differed by
country; participants from the Netherlands had the highest
mean IGF-I concentrations.
There was no signiﬁcant association between serum IGF-I
concentrations and the risk of melanoma in either the basic
model, or in the fully adjusted model, further adjusted for age
at blood collection, education, height, BMI, smoking status,
alcohol intake, marital status, physical activity, and use of
menopausal hormone therapy. In the fully adjusted model,
the OR for a doubling in IGF-I concentration was 1.04 (95%
CI: 0.84–1.28, ptrend = 0.736) (Table 3). When we examined
the associations in prespeciﬁed subgroups, we found no signif-
icant differences in associations by gender, age at blood collec-
tion, BMI, height, age at diagnosis, or years between blood
collection and diagnosis, or by anatomical site or histological
subtype of the tumour (pheterogeneity ≥ 0.078, for all subdivi-
sions) (Table 4).
Discussion
To the best of our knowledge, this is the ﬁrst prospective
study to examine circulating concentration of IGF-I measured
in adulthood in relation to the risk of melanoma. We found
no association overall, or for speciﬁc anatomical sites or histo-
logical subtypes of melanoma. Furthermore, we found no
evidence of heterogeneity in the association between circulat-
ing IGF-I concentrations and risk of melanoma by sex, age at
blood collection, BMI, height, age at diagnosis, or time
between blood collection and diagnosis.
Three small case–control studies have examined circulating
IGF-I concentrations and risk of melanoma, but the ﬁndings
were inconsistent.10–12 The reason for the inconsistency in the
results of these case–control studies is unclear, but the selec-
tion of controls in a case–control study can bias the associa-
tion between exposure and disease.13 In addition, the results
of case–control studies may be inﬂuenced by reverse causation
bias if the presence of disease affects circulating IGF-I
concentrations.
Laboratory work has indicated that the IGF-I axis may play
a role in melanoma progression; speciﬁcally, studies have
reported that IGF-I enhances survival and migration of mela-
noma cells in vitro.19,20 However, the present large prospective
study did not ﬁnd any relation between circulating IGF-I con-
centrations and the risk of developing melanoma.
The strengths of our study include the large sample size, and
the nested-case control design, which allowed for the collection of
blood samples before diagnosis of melanoma. A limitation of our
study is that we did not have information on some of the major
risk factors for melanoma—sun exposure, skin phototype, or fam-
ily history of melanoma2–4–and therefore we were unable to adjust
for these factors in our analysis. However, these factors would only
distort the association of IGF-I with melanoma if they were also
associated with circulating IGF-I concentrations. In a previous
case–control study, adjusting for number of lifetime blistering
sunburns, ability to tan and hair colour did not appreciably alter
the association between IGF-I and melanoma risk.11 In addition,
in our study we used a single measure of circulating IGF-I concen-
tration, but previous work has shown good reproducibility of
Table 3. Odds ratios for melanoma by gender-specific fifths of circulating IGF-I concentration
Gender-speciﬁc ﬁfth
of IGF-I concentration1
Doubling of
concentration
Lowest 2 3 4 Highest OR (95% CI) Ptrend
ncases/ncontrols 259/245 229/245 225/243 267/245 241/243 1221/1221
Basic model2 1.00
(ref )
0.89
(0.69–1.14)
0.88
(0.69–1.13)
1.03
(0.80–1.32)
0.95
(0.73–1.23)
1.05
(0.86–1.29)
0.629
Fully adjusted
model3
1.00
(ref )
0.88
(0.68–1.14)
0.87
(0.67–1.13)
1.01
(0.78–1.31)
0.93
(0.71–1.22)
1.04
(0.84–1.28)
0.736
Abbreviation: OR, odds ratio.
Case and control participants were matched on study centre, sex, age at blood collection ( 1 year) and date ( 3 months), time of day ( 3 hr) and
fasting status (< 3 hr, 3 to 6 hr, > 6 hr) at blood collection.
1The category ranges for IGF-I concentration for men were: 12.71–14.59 nmol/l (lowest fifth), 16.16–17.24 nmol/l, 18.47–19.49 nmol/l,
21.10–23.06 kg/m2 and 25.49–53.08 nmol/l (highest fifth) and for women were: 12.11–13.97 nmol/l (lowest fifth), 15.09–16.30 nmol/l, 17.36–-
18.68 nmol/l, and 20.04–22.19 nmol/l and 25.28–50.23 nmol/l (highest fifth).
2ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above).
3ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above) and adjusted for age at blood collection
(continuous), education (primary/none, secondary, degree, unknown), height (sex-specific quartiles), BMI (sex-specific quartiles), smoking (never, for-
mer, current, unknown), alcohol intake (<1 g, 1–7 g, 8–19 g, 20–39 g, 40 g, unknown), marital status (married/cohabiting, unmarried/not cohabiting,
unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown) and current use of menopausal hormone therapy (no,
yes, unknown or male).
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circulating IGF-I concentrations over three (intra-class correlation
(ICC) = 0.86),21 and ﬁve (ICC = 0.71) years.22 Finally, more than
90% of circulating IGF-I is bound to IGF binding protein
(IGFBP)-323 and we did not measure IGFBPs in our study.
IGFBPs may affect the bioavailability and signalling of IGF-I, but
the regulation of IGF-I action by the IGFBPs is complex and not
fully characterised.6 Prospective studies of breast7 and prostate
cancer,8 have found positive associations with circulating IGF-I
concentrations and cancer risk, that were not changed after adjust-
ment for the predominant binding protein, IGFBP-3.
In conclusion, in this large prospective study, which
included a total of 1,221 cases of incident melanoma, we did
not ﬁnd any evidence that circulating IGF-I concentration
measured in adulthood was associated with the risk of
melanoma.
Data sharing statement
For information on how to submit an application for gaining
access to EPIC data and/or biospecimens, please follow the
instructions at http://epic.iarc.fr/access/index.php.
Table 4. Relationship between circulating IGF-I concentration and risk of melanoma, subdivided by participant and tumour characteristics
ncases/ncontrols OR (95% CI) for a doubling in IGF-I concentration
1 Ptrend Pheterogeneity
Gender
Men 523/523 1.00 (0.71–1.41) 0.983 0.707
Women 698/698 1.04 (0.79–1.38) 0.760
Age at blood collection2
< 55 years 587/587 1.15 (0.82–1.60) 0.423 0.335
 55 years 623/623 0.91 (0.68–1.22) 0.523
BMI3
< 25 kg/m2 315/315 1.56 (0.99–2.45) 0.051 0131
 25 kg/m2 368/368 0.88 (0.60–1.28) 0.496
Height4
< 176 cm (men) or < 163 cm (women) 324/324 0.97 (0.65–1.45) 0.866 0.935
 176 cm (men) or  163 cm (women) 347/347 0.94 (0.62–1.43) 0.771
Age at diagnosis
< 60 years 513/513 1.03 (0.72–1.47) 0.878 0.865
 60 years 708/708 0.98 (0.74–1.29) 0.885
Time between blood collection and diagnosis
< 4 years 361/361 0.79 (0.53–1.18) 0.246 0.078
 4 years 860/860 1.18 (0.91–1.52) 0.212
Tumour characteristics
Anatomical site
Head and neck 125/125 0.47 (0.18–1.22) 0.116 0.468
Trunk 400/400 1.27 (0.87–1.87) 0.217
Upper limbs 244/244 0.89 (0.54–1.48) 0.651
Lower limbs 332/332 1.22 (0.80–1.85) 0.354
Histological subtype
Superficial spreading 537/537 1.01 (0.73–1.40) 0.942 0.249
Nodular melanoma 114/114 0.57 (0.25–1.29) 0.175
Case and control participants were matched on study centre, gender, age at blood collection ( 1 year) and date ( 3 months), time of day ( 3 hr),
and fasting status (< 3 hr, 3 to 6 hr, > 6 hr) at blood collection.
1ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above) and adjusted for age at blood collection
(continuous), height (gender-specific quartiles), BMI (gender-specific quartiles), education (primary/none, secondary, degree, unknown), smoking
(never, former, current, unknown), alcohol intake (<1 g, 1–7 g, 8–19 g, 20–39 g, 40 g, unknown), marital status (married/cohabiting, unmarried/not
cohabiting, unknown), physical activity (inactive, moderately inactive, moderately active, unknown), and current use of menopausal hormone therapy
where appropriate.
2Participants were included in the age at blood collection subgroup analysis if both the case and the matched control were aged <55 years, or if both
the case and the matched control were aged 55 years.
3Participants were included in the BMI subgroup analysis if both the case and the matched control had a BMI <25 kg/m2, or if both the case and the
matched control had a BMI 25 kg/m2.
4Participants were included in the height subgroup analysis if both the case and the matched control had height < 176 cm (men) or < 163 cm (women),
or if both the case and the matched control had height 176 cm (men) or  163 cm (women).
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